FY2025 Earnings Forecast for MNMD Issued By Chardan Capital

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Equities research analysts at Chardan Capital issued their FY2025 EPS estimates for shares of Mind Medicine (MindMed) in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst R. Li expects that the company will post earnings of ($1.70) per share for the year. Chardan Capital has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same quarter in the prior year, the firm earned ($0.59) EPS.

Other analysts also recently issued research reports about the company. Robert W. Baird dropped their price target on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, March 7th. Oppenheimer restated an "outperform" rating and set a $20.00 price objective on shares of Mind Medicine (MindMed) in a research report on Tuesday, December 17th. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Finally, Evercore ISI assumed coverage on Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They set an "outperform" rating and a $23.00 price target on the stock. Ten equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Mind Medicine (MindMed) currently has a consensus rating of "Buy" and a consensus target price of $25.11.

Remove Ads

Mind Medicine (MindMed) Price Performance

Shares of Mind Medicine (MindMed) stock traded down $0.22 during trading on Thursday, hitting $5.97. The stock had a trading volume of 750,950 shares, compared to its average volume of 1,988,946. The firm has a market cap of $450.25 million, a price-to-earnings ratio of -2.64 and a beta of 2.57. Mind Medicine has a 12 month low of $5.03 and a 12 month high of $12.22. The business's 50-day moving average is $7.26 and its 200 day moving average is $6.97. The company has a current ratio of 9.00, a quick ratio of 9.00 and a debt-to-equity ratio of 0.09.

Insiders Place Their Bets

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 21,208 shares of the business's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $142,941.92. Following the transaction, the chief executive officer now owns 856,556 shares in the company, valued at approximately $5,773,187.44. The trade was a 2.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daniel Karlin sold 6,836 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $46,074.64. Following the transaction, the insider now directly owns 446,177 shares of the company's stock, valued at $3,007,232.98. The trade was a 1.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,391 shares of company stock valued at $204,835 in the last ninety days. Company insiders own 2.26% of the company's stock.

Hedge Funds Weigh In On Mind Medicine (MindMed)

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Diadema Partners LP bought a new stake in shares of Mind Medicine (MindMed) during the 4th quarter valued at $33,000. Hollencrest Capital Management grew its stake in shares of Mind Medicine (MindMed) by 10,833.3% during the 4th quarter. Hollencrest Capital Management now owns 7,216 shares of the company's stock valued at $50,000 after purchasing an additional 7,150 shares during the period. King Wealth Management Group purchased a new stake in Mind Medicine (MindMed) during the fourth quarter valued at approximately $70,000. Virtus ETF Advisers LLC purchased a new stake in shares of Mind Medicine (MindMed) in the 4th quarter worth $70,000. Finally, Sharpepoint LLC bought a new position in shares of Mind Medicine (MindMed) in the fourth quarter worth about $71,000. Institutional investors own 27.91% of the company's stock.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.